Literature DB >> 18465473

Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives.

Shareen Y El-Ibiary1, Jennifer M Cocohoba.   

Abstract

OBJECTIVES: To review available information on pharmacokinetic effects of HIV antiretrovirals on hormonal contraceptives.
METHODS: A PubMed search was conducted from 1964 to 2006 using each antiretroviral generic name and the keywords contraceptive, contraception, ethinyl oestradiol, oestrogen, and progestin. Abstracts from the annual Conference on Retroviruses and Opportunistic Infections and International AIDS Society Conferences from 1998-2006 as well as package product inserts were reviewed for completeness.
RESULTS: Antiretroviral regimens containing protease inhibitors and non-nucleoside reverse transcriptase inhibitors may decrease the area under the curve (AUC) levels of steroids released by hormonal contraceptives. Some antiretroviral-hormonal contraceptive pairs do not decrease steroid hormone levels.
CONCLUSION: Pharmacokinetic interactions of antiretrovirals on hormonal contraceptives are specific to the type of antiretroviral and hormonal contraceptive being utilized. HIV-positive women may be counselled to use dual methods of hormonal and barrier contraception to prevent pregnancy with maximal efficacy as well as to reduce possibility of HIV transmission. Oral contraceptives might be administered with non-ritonavir boosted atazanavir or non-ritonavir boosted indinavir without a loss of contraceptive efficacy. Depot medroxyprogesterone acetate may be safe to administer with efavirenz, nevirapine, and nelfinavir. However, further studies are needed to determine the clinical relevance of the interactions between hormonal contraceptives and antiretrovirals and to explore potential dose adjustments to improve contraceptive efficacy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18465473     DOI: 10.1080/13625180701829952

Source DB:  PubMed          Journal:  Eur J Contracept Reprod Health Care        ISSN: 1362-5187            Impact factor:   1.848


  28 in total

1.  Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.

Authors:  Alice Tseng; Michelle Foisy; Christine A Hughes; Deborah Kelly; Shanna Chan; Natalie Dayneka; Pierre Giguère; Niamh Higgins; Cara Hills-Nieminen; Jeff Kapler; Charles J L la Porte; Pam Nickel; Laura Park-Wyllie; Carlo Quaia; Linda Robinson; Nancy Sheehan; Shannon Stone; Linda Sulz; Deborah Yoong
Journal:  Can J Hosp Pharm       Date:  2012-03

Review 2.  Care of the human immunodeficiency virus-infected menopausal woman.

Authors:  Helen Elizabeth Cejtin
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

3.  Examining the contraceptive decisions of young, HIV-infected women: A qualitative study.

Authors:  Jennifer L Brown; Lisa B Haddad; Nicole K Gause; Sarah Cordes; Cecilia Bess; Caroline C King; Kendra Hatfield-Timajchy; Rana Chakraborty; Athena P Kourtis
Journal:  Women Health       Date:  2018-07-24

4.  The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection.

Authors:  Jason J Schafer; Saranyu Ravi; Evelyn V Rowland; Germin Shenoda; Nicholas Leon
Journal:  P T       Date:  2011-06

Review 5.  The Importance of Human Immunodeficiency Virus Research for Transgender and Gender-Nonbinary Individuals.

Authors:  Sara Gianella; J Sonya Haw; Jill Blumenthal; Brooke Sullivan; Davey Smith
Journal:  Clin Infect Dis       Date:  2018-04-17       Impact factor: 9.079

6.  Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.

Authors:  Eric N Ouattara; Xavier Anglaret; Angela Y Wong; Jennifer Chu; Heather E Hsu; Christine Danel; Serge Eholié; Raoul Moh; Delphine Gabillard; Rochelle P Walensky; Kenneth A Freedberg
Journal:  AIDS       Date:  2012-03-13       Impact factor: 4.177

7.  Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi.

Authors:  Gretchen S Stuart; Agnes Moses; Amanda Corbett; Grace Phiri; Wiza Kumwenda; Nkhafwire Mkandawire; Joseph Chintedze; Gabriel Malunga; Mina Hosseinipour; Myron S Cohen; Frank Z Stanczyk; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2011-10-01       Impact factor: 3.731

Review 8.  Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments.

Authors:  Paul J Rowan; Nizar Bhulani
Journal:  World J Hepatol       Date:  2015-09-08

Review 9.  Efavirenz in the therapy of HIV infection.

Authors:  Natella Y Rakhmanina; John N van den Anker
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

10.  Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study.

Authors:  Landon Myer; Rosalind J Carter; Monica Katyal; Patricia Toro; Wafaa M El-Sadr; Elaine J Abrams
Journal:  PLoS Med       Date:  2010-02-09       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.